XWELL Q2 2024 revenue up 14% to $9.3M; net loss narrows to $2.0M from $5.7M

XWELL, Inc.

2024-Q2 EPS reported -$1.08 revenue$18,008,000

Revenue $9.3M (vs $8.2M Q2 2023); operating loss improved to $1.9M from $4.7M.
Net loss attributable to XWELL was $2.0M, down from $5.7M in prior year quarter.
Opened new XpresSpa at Philadelphia airport; plans NYC Penn Station later 2024.
CDC issued new 3-year biosurveillance RFP; XpresTest bidding; contract value similar to prior.
Closed $1.4M registered direct offering at $2.18/share; cash & marketable securities $18.4M, no debt.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.